
Gail E Henderson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4774306/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria. AIDS and Behavior, 2022, 26, 1504-1516.	2.7	4
2	The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. Journal of Personalized Medicine, 2022, 12, 692.	2.5	11
3	Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection. Journal of Virus Eradication, 2022, 8, 100072.	0.5	2
4	Beyond the Medical Model: Retooling Bioethics for the Work Ahead. American Journal of Bioethics, 2021, 21, 53-55.	0.9	2
5	Burden or benefit? Effects of providing education about and the option to request additional genomic findings from diagnostic exome sequencing: A randomized controlled trial. Patient Education and Counseling, 2021, 104, 2989-2998.	2.2	0
6	Ethical, legal and social implications of human genome studies in radiation research: a workshop report for studies on atomic bomb survivors at the Radiation Effects Research Foundation. Journal of Radiation Research, 2021, 62, 656-661.	1.6	1
7	The View from the Benches: Scientists' Perspectives on the Uses and Governance of Human Gene-Editing Research. CRISPR Journal, 2021, 4, 609-615.	2.9	5
8	Parents' perceptions of personal utility of exome sequencing results. Genetics in Medicine, 2020, 22, 752-757.	2.4	37
9	Parallel but connected: Nuances of conducting behavioral and social science research alongside ethically challenging HIV remission trials. Contemporary Clinical Trials Communications, 2020, 19, 100594.	1.1	2
10	Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort. International Health, 2020, 12, 584-590.	2.0	6
11	Development and validation of a measure of comprehension of genomic screening—negative results (CoG-NR). European Journal of Human Genetics, 2020, 28, 1394-1402.	2.8	1
12	Assessing the implications of positive genomic screening results. Personalized Medicine, 2020, 17, 101-109.	1.5	6
13	Recommendations from Thai stakeholders about protecting HIV remission ('cure') trial participants: report from a participatory workshop. International Health, 2020, 12, 567-574.	2.0	4
14	Returning negative results to individuals in a genomic screening program: lessons learned. Genetics in Medicine, 2019, 21, 409-416.	2.4	33
15	Indirect Benefits in HIV Cure Clinical Research: A Qualitative Analysis. AIDS Research and Human Retroviruses, 2019, 35, 100-107.	1.1	35
16	How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS and Behavior, 2019, 23, 2146-2154.	2.7	11
17	Going off antiretroviral treatment in a closely monitored HIV "cure―trial: longitudinal assessments of acutely diagnosed trial participants and decliners. Journal of the International AIDS Society, 2019, 22, e25260.	3.0	23
18	Traditional, complementary, and alternative medical cures for HIV: rationale and implications for HIV cure research. Global Public Health, 2019, 14, 152-160.	2.0	8

GAIL E HENDERSON

#	Article	IF	CITATIONS
19	Psychological adaptation to diagnostic genomic sequencing results: The role of hope fulfillment Health Psychology, 2019, 38, 527-535.	1.6	8
20	Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. Journal of Medical Ethics, 2018, 44, medethics-2017-104433.	1.8	51
21	Grudging Trust and the Limits of Trustworthy Biorepository Curation. American Journal of Bioethics, 2018, 18, 23-25.	0.9	2
22	"Possibly positive or certainly uncertain?― participants' responses to uncertain diagnostic results from exome sequencing. Genetics in Medicine, 2018, 20, 313-319.	2.4	39
23	Navigating the research–clinical interface in genomic medicine: analysis from the CSER Consortium. Genetics in Medicine, 2018, 20, 545-553.	2.4	34
24	Age and perceived risks and benefits of preventive genomic screening. Genetics in Medicine, 2018, 20, 1038-1044.	2.4	8
25	Is Enhancement the Price of Prevention in Human Gene Editing?. CRISPR Journal, 2018, 1, 351-354.	2.9	12
26	Ethical considerations in global HIV phylogenetic research. Lancet HIV,the, 2018, 5, e656-e666.	4.7	39
27	"Forward-Thinking―in U.S. Biobanking. Genetic Testing and Molecular Biomarkers, 2017, 21, 148-154.	0.7	12
28	Online Education and e-Consent for GeneScreen, a Preventive Genomic Screening Study. Public Health Genomics, 2017, 20, 235-246.	1.0	15
29	Distributive justice, diversity, and inclusion in precision medicine: what will success look like?. Genetics in Medicine, 2017, 19, 157-159.	2.4	32
30	ls "incidental finding―the best term?: a study of patients' preferences. Genetics in Medicine, 2017, 19, 176-181.	2.4	34
31	Examining the Cascade of Participant Attrition in a Genomic Medicine Research Study: Barriers and Facilitators to Achieving Diversity. Public Health Genomics, 2017, 20, 332-342.	1.0	8
32	Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 49-60.	0.7	9
33	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
34	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	6.2	137
35	Standardization as performative accountability in biobanking. BioSocieties, 2016, 11, 67-81.	1.3	2
36	The promise and peril of genomic screening in the general population. Genetics in Medicine, 2016, 18, 593-599.	2.4	53

GAIL E HENDERSON

#	Article	IF	CITATIONS
37	With great (participant) rights comes great (researcher) responsibility. Genetics in Medicine, 2016, 18, 124-125.	2.4	0
38	'I can coexist with HIV': a qualitative study of perceptions of HIV cure among people living with HIV in Guangzhou, China. Journal of Virus Eradication, 2016, 2, 170-4.	0.5	17
39	What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53.	0.5	34
40	Genomic screening of the general adult population: key concepts for assessing net benefit with systematic evidence reviews. Genetics in Medicine, 2015, 17, 441-443.	2.4	19
41	The Ethics of HIV "Cure―Research: What Can We Learn from Consent Forms?. AIDS Research and Human Retroviruses, 2015, 31, 56-63.	1.1	43
42	What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53.	0.5	31
43	Public Comments on Proposed Regulatory Reforms That Would Impact Biospecimen Research: The Good, the Bad, and the Puzzling. IRB: Ethics & Human Research, 2015, 37, 1-10.	0.8	5
44	Underutilization of specimens in biobanks: an ethical as well as a practical concern?. Genetics in Medicine, 2014, 16, 738-740.	2.4	23
45	Affected by HIV Stigma: Interpreting Results from a Population Survey of an Urban Center in Guangxi, China. AIDS and Behavior, 2014, 18, 192-201.	2.7	13
46	Social Contexts of Heterosexual Transmission of HIV/STI in Liuzhou City, China. AIDS and Behavior, 2014, 18, 111-117.	2.7	27
47	The Organization of Sex Work in Low- and High-Priced Venues with a Focus on the Experiences of Ethnic Minority Women Working in These Venues. AIDS and Behavior, 2014, 18, 172-180.	2.7	13
48	Population-Based Sexual Behavior Surveys in China: Liuzhou Compared with Other Prefectural Cities. AIDS and Behavior, 2014, 18, 118-125.	2.7	13
49	Framing expectations in early HIV cure research. Trends in Microbiology, 2014, 22, 547-549.	7.7	54
50	Biobanks containing clinical specimens: Defining characteristics, policies, and practices. Clinical Biochemistry, 2014, 47, 245-251.	1.9	28
51	Neglected ethical issues in biobank management: Results from a U.S. study. Life Sciences, Society and Policy, 2013, 9, 1.	3.2	77
52	Recommendations for returning genomic incidental findings? We need to talk!. Genetics in Medicine, 2013, 15, 854-859.	2.4	272
53	Stewardship Practices of U.S. Biobanks. Science Translational Medicine, 2013, 5, 215cm7.	12.4	34
54	Characterizing biobank organizations in the U.S.: results from a national survey. Genome Medicine, 2013, 5, 3.	8.2	157

4

GAIL E HENDERSON

#	Article	IF	CITATIONS
55	Why we should continue to worry about the therapeutic misconception. Journal of Clinical Ethics, 2013, 24, 381-6.	0.3	10
56	A comparison of respondent-driven and venue-based sampling of female sex workers in Liuzhou, China. Sexually Transmitted Infections, 2012, 88, i95-i101.	1.9	41
57	What Research Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011. Journal of Law, Medicine and Ethics, 2012, 40, 1008-1024.	0.9	24
58	Biobanks in the United States: How to Identify an Undefined and Rapidly Evolving Population. Biopreservation and Biobanking, 2012, 10, 511-517.	1.0	21
59	Is Informed Consent Broken?. American Journal of the Medical Sciences, 2011, 342, 267-272.	1.1	55
60	Asking the Right Questions: Views on Genetic Variation Research Among Black and White Research Participants. Journal of General Internal Medicine, 2009, 24, 299-304.	2.6	20
61	Great expectations: views of genetic research participants regarding current and future genetic studies. Genetics in Medicine, 2008, 10, 193-200.	2.4	49
62	Clinical Trials and Medical Care: Defining the Therapeutic Misconception. PLoS Medicine, 2007, 4, e324.	8.4	376
63	Public Willingness to Participate in and Public Opinions About Genetic Variation Research: A Review of the Literature. American Journal of Public Health, 2006, 96, 1971-1978.	2.7	62
64	Therapeutic misconception in early phase gene transfer trials. Social Science and Medicine, 2006, 62, 239-253.	3.8	113
65	Uncertain benefit: investigators' views and communications in early phase gene transfer trials. Molecular Therapy, 2004, 10, 225-231.	8.2	44
66	Vulnerability to Influence: A Two-Way Street. American Journal of Bioethics, 2004, 4, 50-52.	0.9	18
67	HIV/AIDS Risk Among Brothel-Based Female Sex Workers in China: Assessing the Terms, Content, and Knowledge of Sex Work. Sexually Transmitted Diseases, 2004, 31, 695-700.	1.7	166
68	The Rise of Technology in Chinese Hospitals. International Journal of Technology Assessment in Health Care, 1987, 3, 253-263.	0.5	8
69	Scientists' Views on Scientific Self-Governance for Human Genome Editing Research. Human Gene Therapy, 0, , .	2.7	1

5